HC Wainwright Reaffirms “Buy” Rating for Barinthus Biotherapeutics (NASDAQ:BRNS)

HC Wainwright reissued their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a research note issued to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock.

Other equities research analysts have also recently issued reports about the stock. Barclays reduced their target price on shares of Barinthus Biotherapeutics from $7.00 to $3.00 and set an overweight rating for the company in a report on Thursday, June 13th. Alliance Global Partners cut their price target on Barinthus Biotherapeutics from $11.00 to $9.50 and set a buy rating for the company in a research note on Tuesday, August 13th. Finally, William Blair reiterated an outperform rating on shares of Barinthus Biotherapeutics in a report on Thursday, June 13th.

Barinthus Biotherapeutics Price Performance

Shares of BRNS opened at $1.18 on Thursday. Barinthus Biotherapeutics has a 1-year low of $1.11 and a 1-year high of $5.10. The stock has a market cap of $46.06 million, a PE ratio of -0.64 and a beta of -0.53. The firm has a fifty day moving average price of $1.31 and a 200 day moving average price of $1.86.

Barinthus Biotherapeutics (NASDAQ:BRNS) last announced its earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.01). As a group, equities analysts expect that Barinthus Biotherapeutics will post -1.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Barinthus Biotherapeutics

A number of institutional investors have recently modified their holdings of BRNS. DC Funds LP acquired a new stake in Barinthus Biotherapeutics during the first quarter worth about $1,528,000. BlueCrest Capital Management Ltd bought a new position in Barinthus Biotherapeutics during the first quarter valued at about $1,292,000. M&G Plc acquired a new position in Barinthus Biotherapeutics during the second quarter worth about $7,276,000. Ipswich Investment Management Co. Inc. bought a new position in shares of Barinthus Biotherapeutics during the 2nd quarter valued at about $32,000. Finally, Catalina Capital Group LLC acquired a new position in shares of Barinthus Biotherapeutics in the 2nd quarter worth approximately $25,000. Institutional investors and hedge funds own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.